Mar

2026

Timeline of Discovery in Cold Agglutinin Disease

By William Aird

How a laboratory curiosity became a complement-mediated clonal B-cell disease

The history of cold agglutinin disease illustrates how a clinical disorder can emerge at the intersection of several scientific traditions—first appearing as a serologic curiosity, later explained through immunohematology and complement biology, and ultimately recognized as the manifestation of a clonal B-cell disorder.

Early 20th century — A temperature-dependent curiosity

Cold agglutinins were first encountered not as a disease but as a laboratory nuisance. Investigators studying blood group reactions noticed that some sera caused red cells to clump only when the temperature fell, interfering with early serologic experiments and blood typing.

Early work by Karl Landsteiner and others demonstrated that certain antibodies agglutinated red blood cells at low temperatures but lost activity upon warming. These cold-reactive autohemagglutinins disrupted laboratory work but were not yet associated with a distinct disease.

At the time, the phenomenon lived largely in the world of methods rather than medicine. Different investigators described “autohemagglutinins,” “cold hemagglutinins,” and cross-reactive antibodies without a unified concept of a temperature-dependent immune process affecting human red cells.

Clinicians had already reported occasional cases of autohemagglutination and cold-triggered vascular symptoms, but these remained isolated anecdotes rather than a recognized syndrome.

In retrospect, this pattern is familiar in hematology: phenomena first dismissed as technical artifacts often become windows into deeper biological mechanisms.

1910s–1940s — From laboratory artifact to infection marker

Over the next several decades, physicians began noticing that cold agglutinins appeared in patients with certain illnesses, particularly respiratory infections.

By the early 1940s, systematic studies showed that low-titer cold agglutinins were common and often transient. They appeared during a wide variety of conditions, including atypical pneumonia, tracheobronchitis, viral respiratory infections, infectious mononucleosis, and a broad range of other acute and chronic illnesses. In many patients these antibodies emerged during illness and gradually disappeared during recovery.

Importantly, these studies also introduced quantitative thinking. Low titers were common and nonspecific, whereas high titers were rare and strongly associated with severe atypical pneumonia. Even at that time, investigators recognized that the clinical meaning of cold agglutinins depended not simply on their presence but on their magnitude and context.

Despite these observations, the pathogenic significance of cold agglutinins remained uncertain. Editorial commentary of the era emphasized that cold agglutinins were “usually harmless,” noting that they were inactive at body temperature and therefore unlikely to cause hemolysis under normal circumstances.

In retrospect, this period represents a stage in which clinicians learned to separate signal from noise, but stopped short of recognizing a chronic hemolytic disorder. In part this was because chronic anemia accompanied by cold sensitivity was rarely framed as a unified clinical entity, and in part because many investigators explicitly concluded that cold agglutinins were clinically benign.

1957 — The macromolecular nature of cold agglutinins

A major conceptual advance came in the late 1950s when Fudenberg and Kunkel demonstrated that pathogenic cold agglutinins are 19S macroglobulins, the immunoglobulin class now known as IgM.

Using zone electrophoresis and ultracentrifugation, they showed that cold agglutinin activity consistently sedimented with the 19S fraction, whereas the antibodies responsible for warm autoimmune hemolytic anemia resided in the 7S fraction (IgG). This distinction established that cold and warm autoimmune hemolytic anemias were immunologically different diseases.

Their clinical material also hinted at another important insight. Some patients with chronic cold agglutinin disease showed features suggestive of Waldenström macroglobulinemia, including lymphadenopathy, marrow lymphoid infiltration, and circulating macroglobulins. Although the significance of this observation was not yet fully appreciated, it foreshadowed the later recognition that cold agglutinin disease often arises from a clonal B-cell process.

Although these observations hinted at a clonal origin, the tools required to characterize marrow lymphoproliferative disorders did not yet exist, and cold agglutinin disease continued for decades to be classified primarily as a form of autoimmune hemolytic anemia.

This work marked a turning point. Cold agglutinins were no longer simply unusual antibodies. They were defined immunoglobulins with a specific molecular identity, and in modern terms this was the moment when cold agglutinin disease could no longer be treated as merely a variant of warm autoimmune hemolytic anemia.

1960s–1970s — Antigen specificity and membrane biology

The next stage in the story came when immunohematologists began to dissect what these IgM antibodies recognized on red cells.

Investigators identified the I/i antigen system, carbohydrate structures expressed on red-cell membrane glycoproteins. Anti-I antibodies reacted more strongly with adult red cells, whereas anti-i antibodies preferentially reacted with cord cells. This helped explain why clinically significant cold agglutinins in adults almost always display anti-I specificity and why cord blood behaves differently in serologic testing.

Experiments by Rosse and colleagues added a crucial mechanistic insight. They demonstrated that when the I antigen was extracted from the red-cell membrane and placed in solution, it reacted with antibody equally well at 37 °C and 0 °C. In the intact membrane, however, antibody binding was strongly temperature dependent.

This observation suggested that the apparent “cold specificity” of these antibodies was not an intrinsic property of the immunoglobulin itself but rather a feature of how the antigen is presented within the membrane environment. At body temperature the antigen is relatively inaccessible, whereas cooling alters membrane structure and exposes the binding site.

This work placed cold agglutinins squarely within the emerging field of immunohematology, transforming nonspecific clumping phenomena into antigen-specific IgM antibodies interacting with defined membrane structures.

1970s–1980s — Complement biology connects agglutination to hemolysis

Even after antigen specificity was established, an important question remained: how does agglutination lead to hemolysis?

Earlier investigators had proposed explanations such as increased mechanical fragility of clumped red cells. Mechanistic studies in the late twentieth century replaced these ideas with a clearer model based on complement activation.

Experiments showed that when IgM cold agglutinins bind to red cells at lower temperatures, they efficiently fix the first component of complement (C1), initiating the classical complement pathway. This process leads to deposition of complement fragments, particularly C3, on the red-cell membrane.

Work by Rosse and Adams demonstrated that the severity of hemolysis reflects a combination of interacting variables: the concentration of antibody present, the thermal amplitude (the highest temperature at which the antibody can bind), the efficiency with which the antibody fixes complement, and the extent to which complement activation is regulated on the red-cell surface.

These studies also clarified why clinical manifestations vary widely among patients. Some antibodies produce strong agglutination but limited complement activation, leading to acrocyanosis with little anemia. Others efficiently activate complement, producing chronic hemolysis. Most hemolysis occurs through extravascular clearance of C3-coated red cells in the liver, whereas intravascular hemolysis appears when complement activation proceeds further along the cascade.

This era transformed cold agglutinin disease conceptually. What had once been viewed as temperature-dependent clumping was now understood as classical-pathway complement–mediated hemolysis with measurable determinants of disease severity.

Late 20th century–2000s — Recognition of a clonal B-cell disorder

For many years cold agglutinin disease was classified as a form of autoimmune hemolytic anemia of unclear origin.

Gradually, however, clinical and pathologic studies revealed that most patients with chronic cold agglutinin disease produce a monoclonal IgM antibody, usually κ-restricted, derived from a clonal B-cell population.

Bone marrow studies eventually demonstrated a characteristic lymphoproliferative disorder composed of small monoclonal B cells forming nodular aggregates in the marrow. These cells display a distinctive immunophenotype and frequently use the IGHV4-34 gene segment, which encodes part of the antibody’s antigen-binding region and appears uniquely suited to recognize the I antigen on red cells.

Genetic studies showed restricted IGHV4-34 usage with somatic hypermutation while preserving structural features critical for binding the I antigen. The result is a striking example in hematology in which the immunoglobulin gene segment itself helps explain both the antigen specificity of the antibody and the biology of the clonal disorder that produces it.

These findings reframed the disease. Rather than a purely autoimmune phenomenon, cold agglutinin disease came to be recognized as an antibody-mediated hemolytic anemia driven by a marrow-confined clonal B-cell lymphoma with a characteristic immunologic phenotype.

21st century — Mechanism-based therapy

After a century of discovery, these mechanistic insights finally translated into targeted therapy. Once complement activation and clonal B-cell production of IgM were established as the twin pillars of disease pathogenesis, each became an explicit therapeutic target.

Two mechanistic treatment strategies emerged.

Clone-directed therapies, such as rituximab-based regimens, aim to reduce the B-cell population producing the pathogenic IgM antibody. These treatments may produce durable remissions but typically act slowly and carry risks of immunosuppression.

Complement-directed therapies inhibit activation of the classical pathway, preventing complement-mediated destruction of IgM-coated red cells. These treatments can produce rapid improvement in hemolysis but usually require ongoing administration and do not eliminate the underlying B-cell clone. Because cold-induced circulatory symptoms arise largely from agglutination rather than complement activation, these manifestations may persist despite effective control of hemolysis.

Thus modern treatment reflects the dual biology of the disease: one axis targeting the clone, the other targeting the complement pathway.

The conceptual arc of the field

Seen across more than a century, the history of cold agglutinin disease reflects the convergence of several scientific traditions.

Immunohematology transformed cold-reactive autohemagglutinins from laboratory curiosities into antigen-specific IgM antibodies directed against defined red-cell membrane structures.

Complement biology revealed that hemolysis results from classical-pathway activation triggered by IgM bound at low temperatures, with quantifiable determinants such as thermal amplitude and complement fixation efficiency.

Lymphoma biology showed that the pathogenic antibodies usually arise from a stereotyped clonal B-cell population in the bone marrow.

These insights did not emerge in a simple linear sequence. Each was glimpsed partially before the others were fully understood. Together they transformed cold agglutinin disease from a puzzling serologic anomaly into a clinical disorder that sits at the intersection of immunology, complement biology, and clonal hematology.

For clinicians and trainees, this arc is a reminder that diseases located at the boundary between autoimmunity and clonal hematology rarely fit neatly into a single category. The history of cold agglutinin disease shows how classification, mechanism, and therapy evolve together over time, often slowly and nonlinearly, as new scientific tools reveal dimensions of disease that earlier observers could only partially glimpse.

Stay Updated

If you are interested in getting the latest articles from The Blood Project, enter your name and email